Penfigoide ampollar en paciente en tratamiento con nivolumab

• Leopoldo Fernández Dompe ^[1] ; Andrea Estébanez Corrales ^[1] ; Isabel Pinazo Canales ^[1] ; Carlos Monteagudo Castro ^[1]
  1. [1] Hospital Clinico Universitario de Valencia

     Hospital Clinico Universitario de Valencia

     Valencia, España

     
• Localización: Piel: Formación continua en dermatología, ISSN 0213-9251, Vol. 36, Nº. 4 (ABRIL), 2021, págs. 224-226
• Idioma: español
• DOI: 10.1016/j.piel.2020.04.018
• Títulos paralelos:
  • Bullous pemphigoid in a patient under treatment with nivolumab
• Enlaces
  • Texto Completo Ejemplar
• Referencias bibliográficas
  • Wang LL, Patel G, Chiesa-Fuxench ZC, et al. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1...
  • Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the...
  • Aggarwal P. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system....
  • Lopez AT, Geskin L. A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death...
  • Izumi K, Nishie W, Mai Y, et al. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid. J Invest...
  • Panariello L, Fattore D, Annunziata MC, Piantedosi F, Gilli M, Fabbrocini G. Bullous pemphigoid and nivolumab: dermatologic management to...
  • Bakker CV, Terra JB, Pas HH, Jonkman MF. Bullous pemphigoid as pruritus in the elderly a common presentation. JAMA Dermatol. 2013;149(8):950–953.
  • Jour G, Glitza IC, Ellis RM, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a...
  • Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor....
  • Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies....